Fresenius/€FRE
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Fresenius
Fresenius SE & Co. KGaA, operating under the ticker FRE, is a global healthcare group founded in 1912. The company specializes in products and services for dialysis, hospitals, and outpatient medical care. Operating in the healthcare sector, Fresenius provides a range of services including engineering and services for hospitals and other healthcare facilities.
Ticker
€FRE
Sector
Primary listing
XETRA
Industry
Health Care Providers & Services
Headquarters
Employees
175,202
ISIN
DE0005785604
Website
Fresenius Metrics
BasicAdvanced
€24B
56.19
€0.75
0.94
€1.00
2.37%
Price and volume
Market cap
€24B
Beta
0.94
52-week high
€44.40
52-week low
€28.65
Average daily volume
751K
Dividend rate
€1.00
Financial strength
Current ratio
1.429
Quick ratio
0.759
Long term debt to equity
56.776
Total debt to equity
67.912
Dividend payout ratio (TTM)
22.75%
Interest coverage (TTM)
3.48%
Profitability
EBITDA (TTM)
2,592
Gross margin (TTM)
24.28%
Net profit margin (TTM)
1.91%
Operating margin (TTM)
8.12%
Effective tax rate (TTM)
34.07%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
2.57%
Return on equity (TTM)
5.06%
Valuation
Price to earnings (TTM)
56.194
Price to revenue (TTM)
1.073
Price to book
1.23
Price to tangible book (TTM)
11.03
Price to free cash flow (TTM)
14.942
Free cash flow yield (TTM)
6.69%
Free cash flow per share (TTM)
282.30%
Dividend yield (TTM)
2.37%
Forward dividend yield
2.37%
Growth
Revenue change (TTM)
4.61%
Earnings per share change (TTM)
-163.01%
3-year revenue growth (CAGR)
-16.67%
10-year revenue growth (CAGR)
-1.01%
3-year earnings per share growth (CAGR)
-38.47%
10-year earnings per share growth (CAGR)
-9.68%
3-year dividend per share growth (CAGR)
2.82%
10-year dividend per share growth (CAGR)
8.56%
What the Analysts think about Fresenius
Analyst ratings (Buy, Hold, Sell) for Fresenius stock.
Bulls say / Bears say
Fresenius reported a first-quarter EBIT of €654 million, surpassing analyst expectations and confirming its 2025 outlook, indicating strong operational performance. (reuters.com)
JPMorgan raised its price target for Fresenius to €56.90, citing anticipated mid-single-digit revenue and EBIT growth in 2025, reflecting confidence in the company's growth trajectory. (investing.com)
Fresenius achieved €474 million in cost savings by FY24, exceeding its initial FY25 target, demonstrating effective cost management and operational efficiency. (investing.com)
Fresenius reduced its stake in Fresenius Medical Care from 32.2% to 25% plus one share, raising concerns about potential impacts on earnings per share, as the stake contributes approximately 15% to the company's EPS. (investing.com)
The U.S. Federal Trade Commission is investigating Fresenius Medical Care over allegations of restrictive noncompete agreements, which could lead to legal challenges and reputational risks. (bloomberg.com)
Fresenius Medical Care's stock fell 7.8% following the stake reduction by Fresenius SE, indicating potential investor concerns about the company's strategic direction and financial health. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Fresenius Financial Performance
Revenues and expenses
Fresenius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fresenius stock?
Fresenius (FRE) has a market cap of €24B as of July 10, 2025.
What is the P/E ratio for Fresenius stock?
The price to earnings (P/E) ratio for Fresenius (FRE) stock is 56.19 as of July 10, 2025.
Does Fresenius stock pay dividends?
Yes, the Fresenius (FRE) stock pays dividends to shareholders. As of July 10, 2025, the dividend rate is €1 and the yield is 2.37%. Fresenius has a payout ratio of 22.75% on a trailing twelve-month basis.
When is the next Fresenius dividend payment date?
The next Fresenius (FRE) dividend payment date is unconfirmed.
What is the beta indicator for Fresenius?
Fresenius (FRE) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.